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Background: Noninvasive mechanical ventilation (NIV) is a front-line therapy for the management of acute
respiratory failure (ARF) in the intensive care units. However, the data on factors and outcomes associated with the
use of NIV in ARF patients is lacking. Therefore, we aimed to determine the utilization of NIV for ARF in a
population-based study.
Methods: We conducted a populated-based retrospective cohort study, where in all consecutively admitted adults
(≥18 years) with ARF from Olmsted County, Rochester, MN, at the Mayo Clinic medical and surgical ICUs, during
2006 were included. Patients without research authorization or on chronic NIV use for sleep apnea were excluded.
Results: Out of 1461 Olmsted County adult residents admitted to the ICUs in 2006, 364 patients developed ARF, of
which 146 patients were initiated on NIV. The median age in years was 75 (interquartile range, 60–84), 48% females
and 88.7% Caucasians. Eighteen patients (12%) were on Continuous Positive Airway Pressure (CPAP) mode and 128
(88%) were on noninvasive intermittent positive-pressure ventilation (NIPPV) mode. Forty-six (10%) ARF patients
were put on NIV for palliative strategy to alleviate dyspnea. Seventy-six ARF patients without treatment limitation
were given a trial of NIV and 49 patients succeeded, while 27 had to be intubated. Mortality was similar between
the patients initially supported with NIV versus invasive mechanical ventilation (33% vs 22%, P=0.289). In the
multivariate analysis, the development of acute respiratory distress syndrome (ARDS) and higher APACHE III scores
were associated with the failure of initial NIV treatment.
Conclusions: Our results have important implications for a future planning of NIV in a suburban US community
with high access to critical care services. The higher APACHE III scores and the development of ARDS are associated
with the failure of initial NIV treatment.
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Noninvasive mechanical ventilation (NIV) has been exten-
sively used in the patients with acute respiratory failure
(ARF) for more than two decades [1]. Before the start of
NIV in intensive care unit (ICU) during 1990’s [2-5], most
patients with ARF required endotracheal intubation and
invasive mechanical ventilation (IMV), often complicated
by airway injury, barotrauma, ventilation induced acute
lung injury and ventilator associated pneumonia. Several
clinical trials designed to test the efficacy of NIV in 1990’s
showed great mortality benefit among patients with an
acute exacerbation of Chronic Obstructive Lung Disease
(AECOPD) [6,7] and acute cardiogenic pulmonary edema
(ACPE) [8-10]. Besides the use of NIV for AECOPD and
ACPE, the two major ARF etiologies, NIV also facilitates
extubation and weaning in the ICUs [11,12]. NIV has also
been recognized as a way to palliate patients with ARF
who wish to avoid intubation. Palliative NIV can either be
administered to offer a chance for survival, or to alleviate
the symptoms of respiratory distress in terminally ill pa-
tients [13].
Although studies have shown the benefit of NIV in the
treatment of patients with ARF, few epidemiological stud-
ies have investigated the epidemiology of NIV use in ARF
among the critically ill patients. Especially, no population-
based study has been performed to investigate the need
for NIV in a defined community. The Olmsted County in
Rochester, Minnesota, provides a unique opportunity to
conduct a population-based study because of its unique
demographics; relative geographic isolation and critical
care services being provided only by a single tertiary care
medical center [14-16]. Mayo Clinic serves as the only
center capable of providing intensive care services in this
county [17]. The long established Rochester Epidemiology
Projects (REP) facilitates the data collection and ensures
complete case capture from this county [15,16,18].
Therefore, we performed a retrospective population-
based study to examine the use of NIV for ARF in the
critically ill patients, in Olmsted County, Minnesota dur-
ing the year of 2006.
Methods
We conducted a population-based retrospective cohort
study among consecutively admitted adult (≥ 18 years)
patients with ARF at the Mayo Clinic medical and surgi-
cal ICUs in Rochester, MN, from January 1st 2006 to
December 31st 2006. Olmsted county residents were
identified based on the ZIP codes of their primary resi-
dence and verified with the REP database. The REP data-
base is a medical record-linkage system, which links
together the medical records of almost complete Olmsted
County population, irrespective of any demographic or
regional characteristics [15,16]. If a patient had multiple
hospital admissions, only the first ARF episode wasconsidered for analysis. The study protocol was approved
by the Mayo Clinic Institutional Review Board. All eligible
individuals who gave research authorization to review
their medical records for research were included. Patients,
who declined the use of their medical records for research,
required invasive mechanical ventilation for less than 12
hours after surgical procedure and those who used CPAP
treatment for sleep apnea were excluded.
Data abstraction and management
Trained critical care clinical and research fellows ab-
stracted the data from the electronic medical records
(EMR) using a standardized protocol. The causes of NIV
use were identified according to the standard definitions.
The data on demographics, code status preferences, under-
lying severity of pulmonary and nonpulmonary organ
dysfunctions, ventilation type and interface (noninvasive,
endotracheal tube or tracheostomy) were extracted from
the EMR. The Multidisciplinary Epidemiology and Trans-
lational Research in Intensive Care ICU datamart is an
integrative database to extract ICU data from the hospital
EMR [19]. Patient’s baseline characteristics, comorbidities
and severity of illness (Acute Physiology and Chronic
Health Evaluation [APACHE] III) scores, were collected
from the EMR using the ICU datamart. Hemodynamic
variables, fluid, drug infusion, laboratory parameters and
ventilator settings were extracted from the ICU electronic
database. All the relevant data from the patients’ medical
records and bedside flow charts were reviewed from ICU
admission to ICU discharge. The hospital mortality at dis-
charge and hospital length of stay (LOS) was collected
from the electronic database by manual chart review.
Identification of noninvasive mechanical ventilation
The use of NIV was defined as the acute need of positive
pressure ventilatory support through a tightly fitted fa-
cial or nasal mask for more than one hour. Acute re-
spiratory failure was defined as the acute need of IMV
support for more than twelve hours or NIV including
CPAP for more than one hour [20]. Palliative NIV was
defined as patients who themselves signed the “Do Not
Intubate” form and those in whole the health care stuff
considered NIV as the ceiling therapy to alleviate the
symptoms of respiratory failure and offer a possible
chance of survival. The success of NIV was defined as the
recovery from acute respiratory without endotracheal in-
tubation among patients with full code (without limitation
of therapy).
Outcomes
The primary outcome was to identify the incidence of
use of NIV in patients with ARF and to identify the fac-
tors associated with the failure of the NIV among the
same. The secondary outcome was to identify the long
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palliative NIV. The survivors after the hospital discharge
were followed till the end of 2010. The death date was
identified from the EMR or death registration record of
Minnesota, in case of out-of-hospital deaths.
Statistical analysis
All the continuous data was summarized as median
(interquartile range [IQR]). Categorical data was sum-
marized as counts and percentages. Age and gender-
specific incidence rate (95% confidence interval [CI]) for
NIV use in the ICU was calculated assuming that the
entire population of Olmsted County (≥18 years) was at
risk. The incidence rate was adjusted to the projected
2006 United States population (utilizing the data from the
2000 U.S. population census and calculating an expected
1.9% population growth per year). Kaplan-Meier survival
analysis with log-rank test was used to assess the long
term survival among the ARF patients who were initiated
on palliative NIV. A univariate and multivariate logistic
regression analysis was used to identify the factors associ-
ated with failure of NIV in full code patients. Significant
variables on the univariate analysis (p < 0.2) were included
in the multivariate logistic regression model. StepwiseFigure 1 Study outline of noninvasive mechanical ventilation use in t
NIV=non invasive mechanical ventilation.forward and backward procedure was used to select
variables included in the final analysis. Non-significant
factors (p > 0.05) were eliminated (one at a time) until all
remaining factors had a significant association with NIV
failure. JMP statistical software (version 8.0, SAS, Cary,
NC) was used for all the data analyses. The level of signifi-
cance for all statistical tests was 2-sided, with P <0.05.
Results
In 2006, out of 1707 ICU admissions, a total of 1461 unique
Olmsted County adult residents were identified. The study
flowchart was shown in detail in Figure 1. Three hundred
and sixty four patients developed ARF and were ventilated
in ICU, among which 146 (40%) were initiated on the NIV
yielding a cumulative incidence of 180 episodes per 100,000
person-years (95% CI 154~206/100,000) (Figure 1). The
median age in years was 75 (IQR, 60–84), 48% were females
and 88.7% were Caucasians. Eighteen patients (12%) were
on CPAP mode and 128 (88%) were on NIPPV mode.
A total of 76 ARF patients were given an initial trial of
NIV, out of which 49 (69%) patients succeeded, while 27
(31%) had to be intubated. The difference in the baseline
characteristics, severity of illness and reasons for ARF
between the patients who succeeded and failed the initialhe acute respiratory failure patients. ICU= intensive care unit;
Table 1 Baseline characteristics between success and failure of initial NIV treatment
NIV with intubation (n=27) NIV success (n=49) P Value
Age median (IQR), years 60(47–75) 70(59–82) 0.035
Female Sex, N (%) 15(56) 20(41) 0.217
Race, Caucasian (%) 20(77) 42(88) 0.002
PaO2/FiO2 ratio, Mean (SD)
Mean PF ratio 170 (51) 192 (50) 0.088
Lowest PF ratio 91 (52) 149 (68) <0.001
Respiratory rate, mean (SD) 20 (3) 20 (3) 0.769
APACHE III score, median (IQR) 43(33–55) 41(29–55) 0.307
Major indications for NIV, N (%)
Acute on chronic respiratory disorders AECOPD 1(14) 14(29) 0.007
Asthma 0 1(2) 0.999
Other 0 1(2) 0.999
ALI/ARDS 20(74) 4(8) <0.001
Postoperative 1(14) 6(12) 0.999
Congestive heart failure 2(29) 10(20) 0.085
Aspiration 1(4) 1(2) 0.999
Pneumonia 0 2(4) 0.536
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initial NIV treatment were younger and mostly non-
Caucasians. As compared to ARF patients who passed
NIV trial successfully, more acute lung injury/acute re-
spiratory distress syndrome (ALI/ARDS) and less COPD
cases were present in the ARF patients who had to be
intubated (Table 1). In the multivariate analysis, the de-
velopment of ALI/ARDS and higher APACHE III scores
were associated with the failure of initial NIV treatment
(Table 2). NIV was also used in the weaning process for
24 (16%) ARF patients following IMV, of which 14 (58%)
patients were re-intubated.
Forty-six patients chose NIV as their ceiling therapy,
among which 37 (10%) ARF patients were started on pal-
liative NIV and 9 patients were initiated NIV after the
withdrawal of IMV. The major etiology for those 37 pa-
tients initiated with palliative NIV was AECOPD (51%). As
compared to those without COPD who were started with
palliative NIV, the hospital mortality was significantly
lower in the COPD patients (32% vs. 72%, p=0.01). Among
the survivors, median survival time was significantly longerTable 2 Multivariate analysis of failure of NIV
Odds ratio Lower 95% Upper 95% P Value
Age 0.972 0.925 1.016 0.208
APACHE III Score 1.044 1.001 1.094 0.045
ALI/ARDS 33.15 7.539 205.033 <0.001
COPD 0.466 0.022 3.739 0.498
Caucasian 1.104 0.179 7.654 0.916
CHF 1.455 0.22 9.12 0.687in patients with COPD (53 days, 95% CI 9–232) as com-
pared to patients without COPD (8 days, 95% CI 4–30,
p=0.02) (Figure 2). However, when the analysis were re-
stricted in patients with COPD who had treatment limita-
tion versus who did not, patients with treatment limitation
had much higher hospital mortality even after adjusting
for the baseline disease severity (32% vs. 0, p<0.001)
(Table 3).
Discussion
In this study, we showed that NIV was commonly used
in critically ill patients with ARF. NIV was used in two-
third of the patients with ARF for the initial treatment
and palliative care. Twenty percent of patients with ARFFigure 2 Long-term survivals between COPD and no-COPD
patients on palliative NIV use COPD=Chronic Obstructive
Pulmonary Disease NIV=non invasive mechanical ventilation.
Table 3 The comparison between patients with and without treatment limitation
NIV with treatment
limitation (n=19)
NIV without treatment limitation (n=25) P value (treatment
limitation vs. no limitation)IMV= (n=10) NIV without treatment
limitation (n=15)
Age 79(72–85) 69(67–71) 70(59–77) 0.001
Gender 10(53) 0 6(40%) 0.05
Race 16(84) 8(80) 14(93) 0.77
CAD 11(58) 6(60) 7(47) 0.76
Cancer 8(42) 3(30) 6(40) 0.76
Chemotherapy 4(21) 3(30) 1(7) 0.71
CHF 9(47) 3(30) 3(20) 0.12
DM 8(42) 3(30) 7(47) 0.99
Hypertension 17(89) 9(90) 10(67) 0.43
APACHE III score on admission 54(39–62) 45(39–63) 43(23–59) 0.14
ICU length of stay 2(1–3) 4(2–9) 1(1–3) 0.36
Hospital length of stay 6(3–9) 7(5–15) 5(4–8) 0.39
Hospital Mortality 6(32) 0 0 0.008
Median survival after Hospital discharge 43(9–232) 1341(725–2349) 1245(815–2472) <0.001
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NIV trial usually could not rescue the patients with
higher severity of illness and the development of ALI/
ARDS. We did not observe any significant difference in
mortality between the patients who were initially sup-
ported with NIV versus IMV. Palliative NIV did not only
alleviate respiratory distress but also extend the long-
term survival among COPD patients who selected NIV
as the ceiling therapy.
In the last two decades [21], NIV had been used exten-
sively in the ICU settings especially among patients with
ARF because of hypercapnia and cardiogenic pulmonary
edema [5,6,8,11,20,22-24]. However, very few studies had
discussed the use of NIV in a population-based sample
[14,25]. In this population-based study, we showed that
NIV was frequently used in the ICUs. NIV technique was
usually performed in the ICU because of its feasibility and
survival benefits [13,26,27]. In a recently published paper
on the epidemiology of ARF, NIV use increased signifi-
cantly from 3.8% to 10.1% [7]. In our study, we showed
that NIV was used in 40% ARF patients. One of the most
important reasons accounting for the higher use of NIV in
our ICUs was the different method to identify ARF and
NIV. In that paper, the author identified ARF cases using
ICD-9 coding system, which are prone to misclassification
of the ARF cases. We reviewed all the medical records to
identify ARF cases and the NIV uses, which better reflect
the reality of NIV practice in a suburban community ter-
tiary medical center. Our results will be helpful in future
planning for the NIV resource allocation in a community.
Although there was a significant increasing NIV use
trend, it also raised the concern on the safety and potentialdelayed intubation. Many studies had shown that NIV
should be considered as the initial treatment of ARF
caused by AECOPD [5,28], ACPE [8,23,24] and other eti-
ologies [28-30]. Our results also confirmed that AECOPD
and ACPE patients could most likely succeed on the initial
NIV trial. However, patients with ARDS were more likely
to fail the first line NIV treatment, which support the find-
ings of the previous studies [28,31,32]. However, the use of
NIV trial on ARDS remained controversial [31-33]. A re-
cently published randomized clinical trial showed the
benefit of using initial NIV treatment in strictly selected
ALI patients [34], which might not be generalizable in dif-
ferent ICU settings. In this study, the patients with ARF
who succeeded on the NIV trials were younger and less
sick (lower APACHE scores) than those who failed the
NIV trials. The development of ARDS and higher APA-
CHE III scores were strongly associated with the failure of
initial NIV trials in our study, which was similar to previ-
ous observation by Rana et al. [35]. A trial of NIV in spe-
cific populations, such as ARDS patients, might potentially
be harmful because it delayed the intubation and missed
the best window for IMV [32,36]. However, this needs fur-
ther exploration in studies specifically designed to answer
this critical question. Our data did not show a significant
mortality risk among patients who failed initial NIV treat-
ment as compared to patients with initial intubation; while
we did observe a trend toward the higher hospital mor-
tality among patients who failed the initial NIV trial. Al-
though the hospital mortality was not justified by other
important confounding factors, NIV use in ARDS patients
should still be cautious because the chance of success for
NIV trial in this type of ARF had been very low [33,35].
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[13] and nearly half of patients on palliative NIV survived
and went back home, which was similar to our findings.
In the patients on palliative NIV, we also observed that
around fifty percent patients survived and the median sur-
vival after hospital discharge was around 2.6 years during
a four year follow-up. Certainly, the hospital mortality was
significantly higher than those on IMV because of the
baseline comorbidities and severity of disease. Despite an
increasing use of palliative NIV, there is no evidence
showing what type of respiratory failure would receive
the maximum benefit from this technique. Our study did
show that COPD patients might potentially get the best
outcome from palliative NIV. Certainly, palliative NIV
could not extend patients long term survival compared to
patients without treatment limitation. The limited treat-
ment option on NIV should not be always encouraged in
COPD patients due to the worse long-term outcomes.
Our findings were different from the previous report on
DNI patients, wherein, they found no difference in the
quality of life between the patients with and without treat-
ment limitation and after 90 days of receiving NIV treat-
ment for ARF [37]. Part of the reason might be related to
the different study population and study design. Prospect-
ive study tended to recruit a small number of patients
which might not capture the whole population on pallia-
tive care. Our study was a retrospective design and could
only measure the long-term survival without the detailed
information on quality of life. The population in our study
was restricted to the COPD patients which limited our
generalizability. Further prospective studies are needed to
evaluate the benefits of palliative NIV among the critically
ill patients, impact on the health economy, patient’s satis-
faction and long term quality of life after hospital discharge.
Another important use of NIV was to help the
intubated patients wean from IMV. Despite the de-
creased re-intubation rate, less complications, and better
patient outcome, the role of NIV for this indication
remained debatable [38]. In our primary analysis, we
excluded the patients who were started on NIV after
IMV because of withdrawal of care. We did not find
the benefit of NIV trial on the avoidance of the re-
intubation. In a recently published paper, Girault et al.
[39] also showed no benefit on re-intubation rate with
NIV weaning strategy. However, they found that the
NIV might decrease the intubation duration and im-
prove the weaning results in difficult-to-wean chronic
hypercapnic respiratory failure patients. In spite of the
frequent use of NIV in the weaning process, the evidence
of NIV in these patients needs to be further investigated.
Our study had several limitations. Firstly, the retrospec-
tive observational study design raises concerns about the
measured and unmeasured bias and confounding. We en-
sured various measures to enhance the quality of the studyresults, like using a standardized protocol throughout the
study duration for data extraction and identification of the
cases and concerning variables. Also we used the medical
record linkage system to further improve the quality of the
data. The other limitation of our study is the generalizibility
of the results. The restricted mid-western population, pre-
dominantly Caucasian, may limit the generalizability of our
study results. However, the population-based nature and
various steps taken for quality assessment in our study
help in addressing these concerns. Also, studies from the
Olmsted County have consistently shown that their find-
ings are generalizable to the Upper Midwest population
[40], and may also provide important information regarding
various diseases [16]. In addition, during the study duration,
the use of NIV was not consistent on the regular hospital
floors. This might slightly increase the incidence rate of
NIV in ARF patients, however, it is unlikely to have affected
our findings significantly.Conclusion
In conclusion, in this population-based study of Olmsted
County residents, we showed the incidence of NIV use in
patients with ARF was high and NIV was commonly used
as the initial treatment strategy and for palliative care of
ARF in critically ill patients. The development of ARDS
and higher APACHE III score were associated with the
failure of initial NIV treatment. The results of this study
could be helpful in the future planning of noninvasive
mechanical ventilation use in the community-based ICU
settings.
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